Onjuist geneesmiddelgebruik bij ouderen opsporen. De herziene STOPP- en START-criteria

The use of potentially inappropriate medications (PIMs) by older people and potential prescribing omissions (PPOs) represent a serious problem. It increases the risk of adverse drug reactions (ADRs), however it is susceptible to influence in a substantial number of cases. Use of the STOPP/START criteria developed in Ireland to optimise pharmacotherapy of older people reduces the number of ADRs and medication errors. Licensing of new drugs, the increased number of potentially inappropriate drugs, and the availability of new literature were grounds for an update of the first version of the STOPP... Mehr ...

Verfasser: Knol, Wilma
Verduijn, Monique M
Lelie-van der Zande, A C A M Rian
van Marum, Rob J
Brouwers, J R B J Koos
van der Cammen, Tischa J M
Petrovic, Mirko
Jansen, Paul A F
Dokumenttyp: Artikel
Erscheinungsdatum: 2015
Schlagwörter: Drug Prescriptions / Drug-Related Side Effects and Adverse Reactions / Europe / Humans / Inappropriate Prescribing / Medication Errors / Netherlands / Physician's Practice Patterns / Prevalence
Sprache: Niederländisch
Permalink: https://search.fid-benelux.de/Record/base-27219902
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/332015

The use of potentially inappropriate medications (PIMs) by older people and potential prescribing omissions (PPOs) represent a serious problem. It increases the risk of adverse drug reactions (ADRs), however it is susceptible to influence in a substantial number of cases. Use of the STOPP/START criteria developed in Ireland to optimise pharmacotherapy of older people reduces the number of ADRs and medication errors. Licensing of new drugs, the increased number of potentially inappropriate drugs, and the availability of new literature were grounds for an update of the first version of the STOPP/START criteria which was published in 2008. In order to develop a screening tool with a broader application, a consensus panel of experts in the field of pharmacotherapy of older people was selected from 14 European countries for the second version of the STOPP/START criteria, including two from the Netherlands. The translation of the second version of the STOPP/START criteria has been adapted to the situation in the Netherlands, partly by omitting drugs that are not licensed in the Netherlands.